CorMedix (NASDAQ:CRMD) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of CorMedix (NASDAQ:CRMD) in a report published on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock.

A number of other research firms also recently commented on CRMD. Royal Bank of Canada boosted their target price on shares of CorMedix from $11.00 to $12.00 and gave the stock an “outperform” rating in a report on Thursday, December 19th. StockNews.com upgraded shares of CorMedix to a “sell” rating in a report on Friday, November 8th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.67.

CorMedix Trading Up 2.6 %

CRMD stock opened at $10.11 on Wednesday. CorMedix has a 52 week low of $3.03 and a 52 week high of $13.85. The company has a market capitalization of $613.44 million, a price-to-earnings ratio of -12.48 and a beta of 1.57. The firm’s 50-day moving average is $10.47 and its two-hundred day moving average is $9.44.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRMD. FMR LLC grew its position in CorMedix by 54.3% during the third quarter. FMR LLC now owns 4,618 shares of the company’s stock valued at $37,000 after purchasing an additional 1,625 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in CorMedix in the fourth quarter worth approximately $81,000. Captrust Financial Advisors bought a new stake in CorMedix in the fourth quarter worth approximately $90,000. Aigen Investment Management LP bought a new stake in CorMedix in the fourth quarter worth approximately $94,000. Finally, XTX Topco Ltd bought a new stake in CorMedix in the fourth quarter worth approximately $95,000. 34.18% of the stock is owned by hedge funds and other institutional investors.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.